A prospective multi-centre study of susceptibility map-weighted MRI for the diagnosis of neurodegenerative parkinsonism

Young Hee Sung; Joong Seok Kim; Sang Won Yoo; Na Young Shin; Yoonho Nam; Tae Beom Ahn; Dallah Yoo; Kyung Mi Lee; Hyug Gi Kim; Seong Beom Koh; Jinhee Kim; Ilsoo Kim; Do Young Kwon; Younghen Lee; Chulhan Kim; Sun Ju Chung; Sungyang Jo; Seung Hyun Lee; Sang Joon Kim; Minjae Kim; Chul Hyoung Lyoo; Min Seok Baek; Suk Yun Kang; Suk Ki Chang; Sang Won Jo; Seun Ah Lee; Hyeo il Ma; Young Eun Kim; Eun Soo Kim; Yun Joong Kim; Hyun Sook Kim; Min Hee Woo; Hye Jeong Choi; Eung Yeop Kim

doi:10.1007/s00330-021-08454-z

A prospective multi-centre study of susceptibility map-weighted MRI for the diagnosis of neurodegenerative parkinsonism

Young Hee Sung, Joong Seok Kim, Sang Won Yoo, Na Young Shin, Yoonho Nam, Tae Beom Ahn, Dallah Yoo, Kyung Mi Lee, Hyug Gi Kim, Seong Beom Koh, Jinhee Kim, Ilsoo Kim, Do Young Kwon, Younghen Lee, Chulhan Kim, Sun Ju Chung, Sungyang Jo, Seung Hyun Lee, Sang Joon Kim, Minjae KimChul Hyoung Lyoo, Min Seok Baek, Suk Yun Kang, Suk Ki Chang, Sang Won Jo, Seun Ah Lee, Hyeo il Ma, Young Eun Kim, Eun Soo Kim, Yun Joong Kim, Hyun Sook Kim, Min Hee Woo, Hye Jeong Choi, Eung Yeop Kim

Department of Neurology

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

Objectives: This study aimed to compare susceptibility map-weighted imaging (SMwI) using various MRI machines (three vendors) with N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl)nortropane (¹⁸F-FP-CIT) PET in the diagnosis of neurodegenerative parkinsonism in a multi-centre setting. Methods: We prospectively recruited 257 subjects, including 157 patients with neurodegenerative parkinsonism, 54 patients with non-neurodegenerative parkinsonism, and 46 healthy subjects from 10 hospitals between November 2019 and October 2020. All participants underwent both SMwI and ¹⁸F-FP-CIT PET. SMwI was interpreted by two independent reviewers for the presence or absence of abnormalities in nigrosome 1, and discrepancies were resolved by consensus. ¹⁸F-FP-CIT PET was used as the reference standard. Inter-observer agreement was tested using Cohen’s kappa coefficient. McNemar’s test was used to test the agreement between the interpretations of SMwI and ¹⁸F-FP-CIT PET per participant and substantia nigra (SN). Results: The inter-observer agreement was 0.924 and 0.942 per SN and participant, respectively. The diagnostic sensitivity of SMwI was 97.9% and 99.4% per SN and participant, respectively; its specificity was 95.9% and 95.2%, respectively, and its accuracy was 97.1% and 97.7%, respectively. There was no significant difference between the results of SMwI and ¹⁸F-FP-CIT PET (p > 0.05, for both SN and participant). Conclusions: This study demonstrated that the high diagnostic performance of SMwI was maintained in a multi-centre setting with various MRI scanners, suggesting the generalisability of SMwI for determining nigrostriatal degeneration in patients with parkinsonism. Key Points: • Susceptibility map-weighted imaging helps clinicians to predict nigrostriatal degeneration. • The protocol for susceptibility map-weighted imaging can be standardised across MRI vendors. • Susceptibility map-weighted imaging showed diagnostic performance comparable to that of dopamine transporter PET in a multi-centre setting with various MRI scanners.

Original language	English
Pages (from-to)	3597-3608
Number of pages	12
Journal	European Radiology
Volume	32
Issue number	5
DOIs	https://doi.org/10.1007/s00330-021-08454-z
Publication status	Published - 2022 May

Bibliographical note

Funding Information:
This work was supported by a grant from the Heuron Co., Ltd; and a grant from the Basic Research in Science and Engineering Program through the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2021R1C1C1003676).

Publisher Copyright:
© 2021, The Author(s), under exclusive licence to European Society of Radiology.

All Science Journal Classification (ASJC) codes

Radiology Nuclear Medicine and imaging

Access to Document

10.1007/s00330-021-08454-z

Cite this

Sung, Y. H., Kim, J. S., Yoo, S. W., Shin, N. Y., Nam, Y., Ahn, T. B., Yoo, D., Lee, K. M., Kim, H. G., Koh, S. B., Kim, J., Kim, I., Kwon, D. Y., Lee, Y., Kim, C., Chung, S. J., Jo, S., Lee, S. H., Kim, S. J., ... Kim, E. Y. (2022). A prospective multi-centre study of susceptibility map-weighted MRI for the diagnosis of neurodegenerative parkinsonism. European Radiology, 32(5), 3597-3608. https://doi.org/10.1007/s00330-021-08454-z

@article{539faf88ea7a4944aa3a4b382f8bf5fe,

title = "A prospective multi-centre study of susceptibility map-weighted MRI for the diagnosis of neurodegenerative parkinsonism",

abstract = "Objectives: This study aimed to compare susceptibility map-weighted imaging (SMwI) using various MRI machines (three vendors) with N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl)nortropane (18F-FP-CIT) PET in the diagnosis of neurodegenerative parkinsonism in a multi-centre setting. Methods: We prospectively recruited 257 subjects, including 157 patients with neurodegenerative parkinsonism, 54 patients with non-neurodegenerative parkinsonism, and 46 healthy subjects from 10 hospitals between November 2019 and October 2020. All participants underwent both SMwI and 18F-FP-CIT PET. SMwI was interpreted by two independent reviewers for the presence or absence of abnormalities in nigrosome 1, and discrepancies were resolved by consensus. 18F-FP-CIT PET was used as the reference standard. Inter-observer agreement was tested using Cohen{\textquoteright}s kappa coefficient. McNemar{\textquoteright}s test was used to test the agreement between the interpretations of SMwI and 18F-FP-CIT PET per participant and substantia nigra (SN). Results: The inter-observer agreement was 0.924 and 0.942 per SN and participant, respectively. The diagnostic sensitivity of SMwI was 97.9% and 99.4% per SN and participant, respectively; its specificity was 95.9% and 95.2%, respectively, and its accuracy was 97.1% and 97.7%, respectively. There was no significant difference between the results of SMwI and 18F-FP-CIT PET (p > 0.05, for both SN and participant). Conclusions: This study demonstrated that the high diagnostic performance of SMwI was maintained in a multi-centre setting with various MRI scanners, suggesting the generalisability of SMwI for determining nigrostriatal degeneration in patients with parkinsonism. Key Points: • Susceptibility map-weighted imaging helps clinicians to predict nigrostriatal degeneration. • The protocol for susceptibility map-weighted imaging can be standardised across MRI vendors. • Susceptibility map-weighted imaging showed diagnostic performance comparable to that of dopamine transporter PET in a multi-centre setting with various MRI scanners.",

author = "Sung, {Young Hee} and Kim, {Joong Seok} and Yoo, {Sang Won} and Shin, {Na Young} and Yoonho Nam and Ahn, {Tae Beom} and Dallah Yoo and Lee, {Kyung Mi} and Kim, {Hyug Gi} and Koh, {Seong Beom} and Jinhee Kim and Ilsoo Kim and Kwon, {Do Young} and Younghen Lee and Chulhan Kim and Chung, {Sun Ju} and Sungyang Jo and Lee, {Seung Hyun} and Kim, {Sang Joon} and Minjae Kim and Lyoo, {Chul Hyoung} and Baek, {Min Seok} and Kang, {Suk Yun} and Chang, {Suk Ki} and Jo, {Sang Won} and Lee, {Seun Ah} and Ma, {Hyeo il} and Kim, {Young Eun} and Kim, {Eun Soo} and Kim, {Yun Joong} and Kim, {Hyun Sook} and Woo, {Min Hee} and Choi, {Hye Jeong} and Kim, {Eung Yeop}",

note = "Funding Information: This work was supported by a grant from the Heuron Co., Ltd; and a grant from the Basic Research in Science and Engineering Program through the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2021R1C1C1003676). Publisher Copyright: {\textcopyright} 2021, The Author(s), under exclusive licence to European Society of Radiology.",

year = "2022",

month = may,

doi = "10.1007/s00330-021-08454-z",

language = "English",

volume = "32",

pages = "3597--3608",

journal = "European Radiology",

issn = "0938-7994",

publisher = "Springer Verlag",

number = "5",

}

Sung, YH, Kim, JS, Yoo, SW, Shin, NY, Nam, Y, Ahn, TB, Yoo, D, Lee, KM, Kim, HG, Koh, SB, Kim, J, Kim, I, Kwon, DY, Lee, Y, Kim, C, Chung, SJ, Jo, S, Lee, SH, Kim, SJ, Kim, M, Lyoo, CH, Baek, MS, Kang, SY, Chang, SK, Jo, SW, Lee, SA, Ma, HI, Kim, YE, Kim, ES, Kim, YJ, Kim, HS, Woo, MH, Choi, HJ & Kim, EY 2022, 'A prospective multi-centre study of susceptibility map-weighted MRI for the diagnosis of neurodegenerative parkinsonism', European Radiology, vol. 32, no. 5, pp. 3597-3608. https://doi.org/10.1007/s00330-021-08454-z

TY - JOUR

T1 - A prospective multi-centre study of susceptibility map-weighted MRI for the diagnosis of neurodegenerative parkinsonism

AU - Sung, Young Hee

AU - Kim, Joong Seok

AU - Yoo, Sang Won

AU - Shin, Na Young

AU - Nam, Yoonho

AU - Ahn, Tae Beom

AU - Yoo, Dallah

AU - Lee, Kyung Mi

AU - Kim, Hyug Gi

AU - Koh, Seong Beom

AU - Kim, Jinhee

AU - Kim, Ilsoo

AU - Kwon, Do Young

AU - Lee, Younghen

AU - Kim, Chulhan

AU - Chung, Sun Ju

AU - Jo, Sungyang

AU - Lee, Seung Hyun

AU - Kim, Sang Joon

AU - Kim, Minjae

AU - Lyoo, Chul Hyoung

AU - Baek, Min Seok

AU - Kang, Suk Yun

AU - Chang, Suk Ki

AU - Jo, Sang Won

AU - Lee, Seun Ah

AU - Ma, Hyeo il

AU - Kim, Young Eun

AU - Kim, Eun Soo

AU - Kim, Yun Joong

AU - Kim, Hyun Sook

AU - Woo, Min Hee

AU - Choi, Hye Jeong

AU - Kim, Eung Yeop

N1 - Funding Information: This work was supported by a grant from the Heuron Co., Ltd; and a grant from the Basic Research in Science and Engineering Program through the National Research Foundation (NRF) funded by the Korean government (MSIT) (No. 2021R1C1C1003676). Publisher Copyright: © 2021, The Author(s), under exclusive licence to European Society of Radiology.

PY - 2022/5

Y1 - 2022/5

N2 - Objectives: This study aimed to compare susceptibility map-weighted imaging (SMwI) using various MRI machines (three vendors) with N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl)nortropane (18F-FP-CIT) PET in the diagnosis of neurodegenerative parkinsonism in a multi-centre setting. Methods: We prospectively recruited 257 subjects, including 157 patients with neurodegenerative parkinsonism, 54 patients with non-neurodegenerative parkinsonism, and 46 healthy subjects from 10 hospitals between November 2019 and October 2020. All participants underwent both SMwI and 18F-FP-CIT PET. SMwI was interpreted by two independent reviewers for the presence or absence of abnormalities in nigrosome 1, and discrepancies were resolved by consensus. 18F-FP-CIT PET was used as the reference standard. Inter-observer agreement was tested using Cohen’s kappa coefficient. McNemar’s test was used to test the agreement between the interpretations of SMwI and 18F-FP-CIT PET per participant and substantia nigra (SN). Results: The inter-observer agreement was 0.924 and 0.942 per SN and participant, respectively. The diagnostic sensitivity of SMwI was 97.9% and 99.4% per SN and participant, respectively; its specificity was 95.9% and 95.2%, respectively, and its accuracy was 97.1% and 97.7%, respectively. There was no significant difference between the results of SMwI and 18F-FP-CIT PET (p > 0.05, for both SN and participant). Conclusions: This study demonstrated that the high diagnostic performance of SMwI was maintained in a multi-centre setting with various MRI scanners, suggesting the generalisability of SMwI for determining nigrostriatal degeneration in patients with parkinsonism. Key Points: • Susceptibility map-weighted imaging helps clinicians to predict nigrostriatal degeneration. • The protocol for susceptibility map-weighted imaging can be standardised across MRI vendors. • Susceptibility map-weighted imaging showed diagnostic performance comparable to that of dopamine transporter PET in a multi-centre setting with various MRI scanners.

AB - Objectives: This study aimed to compare susceptibility map-weighted imaging (SMwI) using various MRI machines (three vendors) with N-3-fluoropropyl-2-β-carbomethoxy-3-β-(4-iodophenyl)nortropane (18F-FP-CIT) PET in the diagnosis of neurodegenerative parkinsonism in a multi-centre setting. Methods: We prospectively recruited 257 subjects, including 157 patients with neurodegenerative parkinsonism, 54 patients with non-neurodegenerative parkinsonism, and 46 healthy subjects from 10 hospitals between November 2019 and October 2020. All participants underwent both SMwI and 18F-FP-CIT PET. SMwI was interpreted by two independent reviewers for the presence or absence of abnormalities in nigrosome 1, and discrepancies were resolved by consensus. 18F-FP-CIT PET was used as the reference standard. Inter-observer agreement was tested using Cohen’s kappa coefficient. McNemar’s test was used to test the agreement between the interpretations of SMwI and 18F-FP-CIT PET per participant and substantia nigra (SN). Results: The inter-observer agreement was 0.924 and 0.942 per SN and participant, respectively. The diagnostic sensitivity of SMwI was 97.9% and 99.4% per SN and participant, respectively; its specificity was 95.9% and 95.2%, respectively, and its accuracy was 97.1% and 97.7%, respectively. There was no significant difference between the results of SMwI and 18F-FP-CIT PET (p > 0.05, for both SN and participant). Conclusions: This study demonstrated that the high diagnostic performance of SMwI was maintained in a multi-centre setting with various MRI scanners, suggesting the generalisability of SMwI for determining nigrostriatal degeneration in patients with parkinsonism. Key Points: • Susceptibility map-weighted imaging helps clinicians to predict nigrostriatal degeneration. • The protocol for susceptibility map-weighted imaging can be standardised across MRI vendors. • Susceptibility map-weighted imaging showed diagnostic performance comparable to that of dopamine transporter PET in a multi-centre setting with various MRI scanners.

UR - http://www.scopus.com/inward/record.url?scp=85123306989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123306989&partnerID=8YFLogxK

U2 - 10.1007/s00330-021-08454-z

DO - 10.1007/s00330-021-08454-z

M3 - Article

C2 - 35064313

AN - SCOPUS:85123306989

SN - 0938-7994

VL - 32

SP - 3597

EP - 3608

JO - European Radiology

JF - European Radiology

IS - 5

ER -

A prospective multi-centre study of susceptibility map-weighted MRI for the diagnosis of neurodegenerative parkinsonism

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this